Effect of Exercise on Heart Function in Healthy Elderly People
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
|Official Title:||Aerobic Interval Training Reduces and Compensates Age Related Decline in Cardiac Function|
- Improvement of left and right ventricular early diastolic tissue velocity at rest and sub maximal exercise ,e'. [ Time Frame: 12 weeks ]
- Improvement of left and right ventricular systolic tissue velocity function at rest and sub maximal exercise, S'. [ Time Frame: 12weeks ]
|Study Start Date:||November 2008|
|Study Completion Date:||August 2009|
|Primary Completion Date:||March 2009 (Final data collection date for primary outcome measure)|
|Experimental: Exercise intervention||
Other: Aerobic interval training
High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
Aging is associated with a reduced diastolic and systolic function of the heart. Earlier studies have shown that physical exercise can improve both systolic and diastolic function. However the impact on age-related cardiac function is to some extent conflicting. The use of different training intensities will impact on the cardiac result. We have in earlier studies shown aerobic interval training at 90 % of maximal heart rate (4x4 minutes) to have more impact on cardiac function, endothelial function and maximal oxygen uptake compared to moderate intensity.
To our knowledge the effect of aerobic interval training on cardiac function has not been studied in an old, sedate group before.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00804518
|Trondheim, Sør-Trøndelag, Norway, 7489|
|Principal Investigator:||Charlotte Bjork Ingul, PhD||NTNU|